Metraipolis › archive › dc_9ce76ef088e7

Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report — Europe PMC PMID:42621040

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42621040
DOI
10.3389/fphar.2026.1890595
License (as archived)
solo-consultazione
Archived
2026-10-17T02:07:35.271Z
SHA-256 of the archived text
64624c546508a82ebee4d662794cb3f900608a88db37c3832cf0b5208840a1f2
Stable URL of this page
https://metraipolis.com/documento/dc_9ce76ef088e7

How to cite

Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report — Europe PMC PMID:42621040 — Europe PMC (en), https://europepmc.org/article/MED/42621040 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9ce76ef088e7 (Metraipolis archive dc_9ce76ef088e7, sha256 64624c546508a82ebee4d662794cb3f900608a88db37c3832cf0b5208840a1f2)
BibTeX
@misc{dc9ce76ef088e7,
  title = {Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report — Europe PMC PMID:42621040},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42621040},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9ce76ef088e7; sha256 64624c546508a82ebee4d662794cb3f900608a88db37c3832cf0b5208840a1f2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42621040. Agents can read the archived copy with the MCP tool read_document.